AR063311A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
AR063311A1
AR063311A1 ARP070104573A ARP070104573A AR063311A1 AR 063311 A1 AR063311 A1 AR 063311A1 AR P070104573 A ARP070104573 A AR P070104573A AR P070104573 A ARP070104573 A AR P070104573A AR 063311 A1 AR063311 A1 AR 063311A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
lower alkyl
hydrogen
formula
Prior art date
Application number
ARP070104573A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR063311A1 publication Critical patent/AR063311A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

La presente proporciona compuestos de la siguiente estructura: A-L1-B-C-D que son utiles para el tratamiento o la prevencion de las condiciones o los trastornos asociados con la actividad de DGAT1 en animales, en particular en seres humanos. Reivindicacion 1: Un compuesto que tiene la siguiente estructura: A-L1-B-C-D y sales farmacéuticamente aceptables y pro-fármacos del mismo, en donde: A se selecciona a partir de un alquilo sustituido o insustituido, alcoxilo sustituido o insustituido, cicloalquilo sustituido o insustituido, arilo sustituido o insustituido, y un heterociclilo sustituido o insustituido, en donde A está enlazado con L1 por medio de un miembro de carbono del anillo, cuando A es un anillo, L1 se selecciona a partir del grupo que consiste en: un grupo amina de la formula -(CH2)n-(CR4R4')p-(CH2)m-N(R3)-, un grupo tiocarbamoílo de la formula -(CH2)n-(CR4R4')p(CH2)m-N(R3)-C(S), un grupo amida de la formula -C(O)-N(R3)-(CH2)n-(CR4R4')p-(CH2)m-, un grupo amidina de la formula -C(NH)-N(R3)-(CH2)n-(CR4R4')p(CH2)m-, un grupo amida de la formula -(CH2)n-(CR4R4')p-(CH2)m-C(O)-N(R3)-, un grupo sulfonamida de la formula -(CH2)n-(CR4R4')p-(CH2)mS(O2)-N(R3)-, un grupo carbamato de la formula -(CH2)n- (CR4R4')p-(CH2)m-(O)-C(O)-N(R3)-, o un grupo urea de la formula -(CH2)n--(CR4R4')p-(CH2)m-N(R3)-C (O)-N(R3A)-, en donde: R3 y R3A son, independientemente uno del otro, hidrogeno o alquilo inferior, m, n, y p son, independientemente unos de otros, un entero de 0 a 2, R4 y R4' son, independientemente uno del otro, hidrogeno, halogeno, hidroxilo, alcoxilo inferior, alcoxilo inferior-carbonilo, carboxilo, o alquilo inferior, o R4 y R4' se unen juntos para formar un residuo espiro de la formula (2) en donde: X es NR3', O, S, o CR3-R4-, r y s son, independientemente uno del otro, cero o un entero de 1 a 3, R3' es hidrogeno o alquilo inferior, R3ö es hidrogeno, halogeno, hidroxilo, alcoxilo, o alquilo inferior, R4ö es hidrogeno o alquilo inferior, B es un grupo heteroarilo divalente sustituido o insustituido seleccionado a partir de uno de los siguientes grupos de formulas (3) en donde X1 y X2' se seleccionan independientemente a partir de O, NH, NR9 o S, en donde R9 se selecciona a partir de alquilo inferior, alquilo inferior-amino, alcoxilo inferior-alquilo, hidroxi-alquilo inferior, X1', X2, X3, y X4 se seleccionan independientemente a partir de N o CH, C es como en formula (4) en donde R1 se selecciona a partir de H, ciano, alquilo inferior-sulfonil-amino, alcanoil-amino, halogeno, alquilo inferior, trifluoro-metilo, alcoxilo inferior, alquilo inferior-amino, dialquilo inferior-amino, y NO2, R'1, R2, y R'2 se seleccionan independientemente a partir de hidrogeno, halogeno, trifluoro-metilo, ariloxilo, alquilo inferior, alcoxilo inferior, alquilo inferior-amino, dialquilo inferior-amino, y NO2, o C también puede ser un grupo arilo o heteroarilo bicíclico sustituido o insustituido, D se selecciona a partir de hidrogeno, halogeno, hidroxilo, ciano, alcanoil-amino, carboxilo, carbamoílo, -O-L2-E, -S-L2-E', -C(O)-O-L2-E, -L2-Eö, y -NR6-L2-E', L2 es -(CH2)n'-(CR5R5')p'-(CH2)m'-, E es: alquilo, acilo, alcoxi-carbonilo, ácido fosfonico, fosfonato, cicloalcoxi- carbonilo, ariloxi-carbonilo, heterocicliloxi-carbonilo, carboxilo, carbamoílo, sulfonilo, -SO2-OH, sulfamoílo, sulfonil carbamoilo, sulfoniloxilo, sulfonamido, -C(O)-O-R-PRO, arilo sustituido o insustituido, heterociclilo sustituido o insustituido, o heteroarilo sustituido o insustituido, y, cuando n' + m' + p' es igual a cero, E no es sulfoniloxilo o sulfonamido, E' es: alquilo, arilo, alcoxi-carbonilo, cicloalcoxi-carbonilo, ariloxi carbonilo heterocicliloxi-carbonilo, carboxilo, carbamoílo, sulfonil carbamoilo, sulfonilo, -SO2-OH, sulfamoílo, sulfonamido, ácido fosfonico, fosfonato, sulfoniloxilo, -C(O)-O-R-PRO, arilo sustituido o insustituido, heterociclilo sustituido o insustituido, o heteroarilo sustituido o insustituido, y, cuando n' + m' + p' es igual a cero, E' no es sulfamoílo, sulfonamido, ácido fosfonico, fosfonato, o sulfoniloxilo, Eö es: alquilo, acilo, alcoxi-carbonilo, ácido fosfonico, fosfonato, cicloalcoxi-carbonilo, ariloxi-carbonilo, heterocicliloxi-carbonilo, carboxilo, carbamoílo, sulfonilo, sulfamoílo, sulfoniloxilo, sulfonamido, -SO2-OH, sulfonil-carbamoilo, -C(O)-O-R-PRO, arilo sustituido o insustituido, heterociclilo sustituido o insustituido, o heteroarilo sustituido o insustituido, m', n', y p' son, independientemente unos de otros, un entero de 0 a 4, m' + n' + p' es entre 0 y 12, de preferencia 0, 1, 2, 3, o 4, R5 y R5' son, independientemente uno del otro, hidrogeno, halogeno, hidroxilo, alcoxilo inferior, o alquilo inferior, o R5 y R5' se unen juntos para formar un residuo espiro de la formula (5) en donde X' es NRx, O, S, o CRx'Rxö, r' y s' son, independientemente uno del otro, cero o un entero de 1 a 3, Rx es hidrogeno o alquilo inferior, Rx' es hidrogeno, halogeno, hidroxilo, alcoxilo, o alquilo inferior, Rxö es hidrogeno o alquilo interior; o un estereoisomero, enantiomero, o tautomero del mismo, una sal farmacéuticamente aceptable del mismo, o un pro-fármaco del mismo.
ARP070104573A 2006-10-18 2007-10-16 Compuestos organicos AR063311A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82998006P 2006-10-18 2006-10-18
US95234107P 2007-07-27 2007-07-27

Publications (1)

Publication Number Publication Date
AR063311A1 true AR063311A1 (es) 2009-01-21

Family

ID=39276877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104573A AR063311A1 (es) 2006-10-18 2007-10-16 Compuestos organicos

Country Status (15)

Country Link
US (1) US8222248B2 (es)
EP (1) EP2074089B1 (es)
JP (1) JP5298022B2 (es)
KR (1) KR20090071642A (es)
AR (1) AR063311A1 (es)
AU (1) AU2007311087B2 (es)
BR (1) BRPI0718478A2 (es)
CA (1) CA2666880A1 (es)
CL (1) CL2007002974A1 (es)
ES (1) ES2440253T3 (es)
MX (1) MX2009004047A (es)
PE (1) PE20080888A1 (es)
RU (1) RU2009118489A (es)
TW (1) TW200829563A (es)
WO (1) WO2008048991A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
CN101472905B (zh) 2006-05-30 2011-12-14 阿斯利康(瑞典)有限公司 作为酰基辅酶甘油二酯酰基转移酶的抑制剂的取代的5-苯基氨基-1,3,4-噁二唑-2-基羰基氨基-4-苯氧基-环己烷甲酸
EP2041099A1 (en) 2006-05-30 2009-04-01 AstraZeneca AB 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors
WO2009081195A1 (en) 2007-12-20 2009-07-02 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2010039668A2 (en) * 2008-10-01 2010-04-08 The Regents Of The University Of California Inhibitors of cyclin kinase inhibitor p21
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
AR075858A1 (es) * 2009-03-18 2011-05-04 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
SG177740A1 (en) * 2009-07-23 2012-02-28 Univ Vanderbilt Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators
KR101194995B1 (ko) * 2009-10-14 2012-10-29 주식회사 이큐스앤자루 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CN103025383B (zh) 2010-06-01 2015-03-25 萨米特公开有限公司 用于治疗艰难梭菌相关疾病的化合物
CA2860672A1 (en) 2012-01-06 2013-07-11 University Of South Florida Compositions, methods of use, and methods of treatment
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
MY175865A (en) 2013-12-19 2020-07-14 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
MX371017B (es) 2014-02-03 2020-01-13 Vitae Pharmaceuticals Llc Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
WO2015166398A1 (en) * 2014-04-30 2015-11-05 Aurigene Discovery Technologies Limited 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
SG11201702362SA (en) 2014-10-14 2017-04-27 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11384081B2 (en) 2016-09-20 2022-07-12 Centre Leon Berard Benzoimidazole derivatives as anticancer agents
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
CA3110576A1 (en) * 2018-09-18 2020-03-26 Terns, Inc. Compounds for treating certain leukemias
WO2020120576A1 (en) * 2018-12-11 2020-06-18 Fundació Institut De Recerca Biomèdica (Irb Barcelona) p38α AUTOPHOSPHORYLATION INHIBITORS
BR112022000325A2 (pt) 2019-07-11 2022-03-15 Escape Bio Inc Indazois e azaindazois como inibidores de lrrk2
MX2022009025A (es) * 2020-01-28 2022-10-07 Protego Biopharma Inc Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4259607A1 (en) * 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
TW202329955A (zh) * 2022-01-12 2023-08-01 英屬開曼群島商百濟神州有限公司 作為ＤＮＡ聚合酶Ｔｈｅｔａ抑製劑之噻唑并吡啶基醯胺衍生物
EP4265247A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells
US11970468B1 (en) 2023-10-23 2024-04-30 King Faisal University 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
JPH0678308B2 (ja) * 1985-04-24 1994-10-05 三共株式会社 フタルイミド誘導体およびそれを含有する農園芸用殺菌剤
BR9612434A (pt) 1995-12-28 1999-12-28 Fujiwasa Pharmaceutical Co Ltd Derivados de benzimidazol
EP0963371B1 (en) 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
US6251689B1 (en) * 1998-05-14 2001-06-26 Telik, Inc. Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
PT1194425E (pt) * 1999-06-23 2005-10-31 Aventis Pharma Gmbh Benzimidazoles substituidos
WO2001014343A1 (en) 1999-08-26 2001-03-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JP5010089B2 (ja) * 2000-09-19 2012-08-29 スピロジェン リミテッド Ｃｃ−１０６５およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
FR2821721B1 (fr) * 2001-03-08 2004-07-09 Laurent Locatelli Composition pour alimentation animale, utilisation de cette composition, et produit pour alimentation animale comprenant cette composition
EP1368028B1 (en) * 2001-03-12 2007-08-15 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
ATE369854T1 (de) * 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1455815A4 (en) 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003242233A1 (en) * 2002-06-12 2003-12-31 Bf Research Institute, Inc. Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation
EP1550462B1 (en) * 2002-08-06 2012-01-25 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
CA2509202A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
CN1795193B (zh) 2003-05-20 2010-08-18 诺瓦提斯公司 用作过氧化物酶体增殖物激活受体的配体的n-酰基含氮杂环化合物
JPWO2005108370A1 (ja) * 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
EP1805156B1 (en) 2004-10-15 2010-12-22 Bayer HealthCare LLC Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
ES2400287T3 (es) * 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
EP1960382A1 (en) * 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
EP1986633B1 (en) * 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
TW200829563A (en) 2008-07-16
MX2009004047A (es) 2009-07-21
EP2074089A2 (en) 2009-07-01
AU2007311087B2 (en) 2012-03-01
BRPI0718478A2 (pt) 2013-11-26
CA2666880A1 (en) 2008-04-28
KR20090071642A (ko) 2009-07-01
EP2074089B1 (en) 2013-09-18
WO2008048991A2 (en) 2008-04-24
US8222248B2 (en) 2012-07-17
JP5298022B2 (ja) 2013-09-25
JP2010506950A (ja) 2010-03-04
RU2009118489A (ru) 2010-11-27
ES2440253T3 (es) 2014-01-28
US20110046133A1 (en) 2011-02-24
CL2007002974A1 (es) 2008-05-23
PE20080888A1 (es) 2008-08-26
WO2008048991A3 (en) 2008-07-10
AU2007311087A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
AR063311A1 (es) Compuestos organicos
AR066169A1 (es) Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
NI201900029A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR055959A1 (es) Derivados espiro para la modulacion de actividad de crth2
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
AR072839A1 (es) Derivados adamantil diamida y usos de los mismos
AR085425A1 (es) Inhibidores de la glucosilceramida sintasa
AR050194A1 (es) Analogos de biaril piperazinil-piridina sustituidos
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR064491A1 (es) Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CO6230982A2 (es) Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen
AR043674A1 (es) Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa
AR051290A1 (es) Derivados de hidantoina sustituidas
AR040476A1 (es) N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
ECSP088129A (es) Derivado novedoso de heterocicliden acetamida
AR058701A1 (es) Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR054000A1 (es) Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal